



PRESS RELEASE

MaxiVAX announces that US FDA accepts Investigational New Drug Application for its novel active immunization anti-cancer therapy, MVX-ONCO-1

- **MVX-ONCO-1 triggers patient's own natural immune response mechanism via innovative technology to eliminate cancer cells**

Geneva, Switzerland, 17 July 2018 - MaxiVAX SA, a private Swiss clinical-stage biotech company developing novel anti-cancer vaccines, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application to conduct clinical trials in the US with its product MVX-ONCO-1.

Dimitrios Goundis, PhD, Chief Executive Officer, commented: "The FDA's acceptance of our IND is a significant milestone for MaxiVAX. This decision validates the product attributes of MVX-ONCO-1, the promise of the preclinical and clinical data, and the quality of our production & control systems. Above all it is testament to the ingenuity and expertise of our team who are determined to make this significant potential cancer therapy available to patients as soon as possible."

The company's MVX-ONCO-1 product triggers a patient's own natural immune response mechanism using the patient's own irradiated cancer cells as vaccine antigens, combined with an immune boosting agent.

About MVX-ONCO-1

MVX-ONCO-1 is a biological product made up of two components. The first consists of complete tumor cells taken from each individual patient and represents the best repertoire of antigens, i.e., cancer-specific targets against which a coordinated immune response can be directed. The cancer cells are lethally irradiated before being implanted subcutaneously in the patient.

The second component consists of the adjuvant, or booster. Adding a strong adjuvant is essential for triggering an efficient immune response. The release of the potent adjuvant GM-CSF, a white blood cell growth factor, is obtained by the implantation of a biocompatible capsule that contains a cell line genetically modified to produce the strong adjuvant. The encapsulation of the GM-CSF-producing cells allows the continuous, *in-situ* delivery of the immune boosting agent over seven days at the site of immunization. This is a critical parameter for the successful and sustained immunization against the cancer cells.

An ongoing Phase 1 clinical trial demonstrates that MVX-ONCO-1 is safe and well tolerated, with encouraging efficacy results. MVX-ONCO-1 is the company's first compound, for which there is IP protection in both the United States and the European Union.

About MaxiVAX www.maxivax.ch

MaxiVAX is a private Swiss clinical-stage biotech company with a novel, patient-specific and personalized active immunotherapy treatment for cancer. MaxiVAX received the 2017 CTI Swiss Medtech Award for its ground-breaking work with MVX-ONCO-1, which is in Phase 2 development for Head & Neck cancer in Switzerland.

Investor and Business Development Contact

Dimitrios Goundis Ph.D.

CEO

E-mail: dgoundis@maxivax.ch

Phone: +41 79 866 1430

MaxiVAX SA

Rue de l'Athénée 24

CH-1206 Geneva, Switzerland

Media Contact

Nick Miles / Toomas Kull

Cabinet Privé de Conseils s.a.

Geneva, Switzerland

Phone: +41 22 552 46 46

Mobile: +41 79 678 76 26

Mobile: +41 76 748 01 74

E-mail: miles@cpc-pr.com

kull@cpc-pr.com

Edward Agne

The Communications Strategy Group Inc.

Cambridge, Massachusetts, USA

Phone: +1 781 631 3117

Mobile: +1 781 888 0099

E-mail: edagne@comstratgroup.com